Add this topic to your myFT Digest for news straight to your inbox
For stretched public health budgets, high-tech treatments are hard to afford but some pre-emptive measures can prove good value
Danish group beats expectations with first-quarter sales up 24% and raises annual forecast on high demand
Wellcome’s John-Arne Røttingen says divisions risk harming action on pandemic responses and ‘superbugs’
The UK is a world leader in finding new treatments to tackle diseases
Drugmaker could fast track subsidiary’s bankruptcy process if 75% of claimants vote in favour of new plan
Quarterly results beat expectations and signal strong start for pharma group
US pharma group follows Eli Lilly with website for patients to obtain medication online
Shares of world’s most valuable pharmaceuticals group reapproach record highs
US state to buy naloxone nasal spray from generics maker and distribute medication under its own brand
Research is finding ways to extend animal lifespans but regulators are still wary of treating ageing as a disease
With revenues having more than doubled since 2019, to $10bn, US pharma group targets painkillers
Success of biosimilars in lowering prices will depend on decisions from powerful pharmacy benefit managers
Biosecure Act would prohibit American companies receiving federal grant money from working with some Chinese groups
Continent’s drugmakers need to pay up to attract and retain talent, says Pascal Soriot
Neglecting women’s pain affects the entire medical pipeline, from research to diagnosis and treatment
Admonitions about staff trading in their employer’s shares may now need to be broadened
Judge to decide on admission of evidence as part of litigation that has knocked billions off pharma group’s value
Swiss pharma group has jettisoned 16 drugs that ‘don’t have the promise to be transformative medicines’
WPP-owned advertising agency seeks to tap trend for seeking medical information on social media
Technique highlights concerns shifting global disease burden as populations age
Pfizer’s Emblaveo to be aimed at some of the most dangerous drug-resistant bacteria
High costs and concerns over efficacy and side effects limit uptake of first treatment as another nears approval
Ochre Bio partnering with Germany’s Boehringer Ingelheim on treatments that will harness the organ’s capacity to regenerate
Moderna alleges Pfizer and BioNTech infringed its patents in use of mRNA platform
Factory inspectors refuse to visit country over fears they could fall foul of tightened rules
International Edition